Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program

Expert Opinion on Drug Safety ◽

10.1517/14740338.2014.939583 ◽

2014 ◽

Vol 13 (9) ◽

pp. 1165-1173 ◽

Author(s):

Daniel Castellano ◽

Luis M Antón Aparicio ◽

Emilio Esteban ◽

Alfredo Sánchez-Hernández ◽

Jose Ramón Germà ◽

...

Keyword(s):

Prostate Cancer ◽

Safety Data ◽

Castration Resistant Prostate Cancer ◽

Expanded Access ◽

Castration Resistant ◽

Expanded Access Program ◽

Download Full-text

Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5051 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5051-5051 ◽

Author(s):

Anthony M. Joshua ◽

Neal D. Shore ◽

Fred Saad ◽

Kim N. Chi ◽

Carl A. Olsson ◽

...

Keyword(s):

Prostate Cancer ◽

United States ◽

The United States ◽

Castration Resistant Prostate Cancer ◽

Expanded Access ◽

Castration Resistant ◽

Expanded Access Program ◽

Previously Treated ◽

Download Full-text

715 CABAZITAXEL FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): FINAL QUALITY OF LIFE (QOL) RESULTS WITH SAFETY DATA FROM THE UNITED KINGDOM (UK) EARLY ACCESS PROGRAMME (EAP) (NCT01254279)

The Journal of Urology ◽

10.1016/j.juro.2013.02.274 ◽

2013 ◽

Vol 189 (4S) ◽

Author(s):

Amit Bahl ◽

Susan Masson ◽

Zafar Malik ◽

Alison Birtle ◽

Santhanam Sundar ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

United Kingdom ◽

Safety Data ◽

Castration Resistant Prostate Cancer ◽

Early Access ◽

The United Kingdom ◽

Castration Resistant ◽

Access Programme

Download Full-text

Efficacy and Safety Data of Taiwan Breast Cancer Patients Enrolled in the Lapatinib Expanded Access Program (LEAP).

10.1158/0008-5472.sabcs-09-5093 ◽

2009 ◽

Author(s):

S. Chen ◽

C. Huang ◽

C. Tsao ◽

M. Liu ◽

D. Yeh ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Safety Data ◽

Efficacy And Safety ◽

Breast Cancer Patients ◽

Expanded Access ◽

Expanded Access Program ◽

Download Full-text

Post hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry

Annals of Oncology ◽

10.1093/annonc/mdy284.027 ◽

2018 ◽

Vol 29 ◽

pp. viii284-viii285

Author(s):

Z. Malik ◽

A. Pichler ◽

G. Di Lorenzo ◽

U. De Giorgi ◽

S. Hitier ◽

...

Keyword(s):

Prostate Cancer ◽

Treatment Duration ◽

Castration Resistant Prostate Cancer ◽

Compassionate Use ◽

Post Hoc Analysis ◽

Expanded Access ◽

Castration Resistant ◽

Baseline Characteristics ◽

Post Hoc ◽

Access Programs

Download Full-text

Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)

Annals of Oncology ◽

10.1093/annonc/mdw372.35 ◽

2016 ◽

Vol 27 ◽

pp. vi255 ◽

Author(s):

D. Heinrich ◽

S. Gillessen ◽

A. Heidenreich ◽

D. Keizman ◽

J.M. O'Sullivan ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Alkaline Phosphatase ◽

Castration Resistant Prostate Cancer ◽

Early Access ◽

Castration Resistant ◽

Download Full-text

Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)

Annals of Oncology ◽

10.1093/annonc/mdx423.007 ◽

2017 ◽

Vol 28 ◽

pp. vi19 ◽

Author(s):

G. Procopio ◽

G. Paganelli ◽

M. Cabria ◽

E. Cortesi ◽

M. Tucci ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Alkaline Phosphatase ◽

Castration Resistant Prostate Cancer ◽

Early Access ◽

Castration Resistant ◽

Download Full-text

Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer

Future Oncology ◽

10.2217/fon.13.256 ◽

2014 ◽

Vol 10 (6) ◽

pp. 975-983 ◽

Author(s):

Sergio Bracarda ◽

Angela Gernone ◽

Donatello Gasparro ◽

Paolo Marchetti ◽

Monica Ronzoni ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Early Access ◽

Castration Resistant ◽

Download Full-text

Radium-223 (Ra-223) Therapy after Abiraterone: Analysis of Symptomatic Skeletal Events (SSEs) in an International Early Access Program (iEAP) in Patients with Metastatic castration-Resistant Prostate Cancer (mCRPC)

Journal of Medical Imaging and Radiation Sciences ◽

10.1016/j.jmir.2019.03.122 ◽

2019 ◽

Vol 50 (1) ◽

pp. S40

Author(s):

Joe M. O’sullivan ◽

Kurt Miller ◽

Daniel Heinrich ◽

Joan Carles ◽

Manfred Wirth ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Early Access ◽

Castration Resistant ◽

Download Full-text

Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)

Annals of Oncology ◽

10.1093/annonc/mdx423.006 ◽

2017 ◽

Vol 28 ◽

pp. vi18-vi19 ◽

Author(s):

G. Paganelli ◽

G. Procopio ◽

M. Cabria ◽

E. Cortesi ◽

M. Tucci ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Early Access ◽

Castration Resistant ◽

Bone Targeting ◽

Download Full-text

Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy

Annals of Oncology ◽

10.1093/annonc/mdx371.051 ◽

2017 ◽

Vol 28 ◽

pp. v318

Author(s):

R. Sabbatini ◽

L. Galli ◽

S. Pignata ◽

G. Lo Re ◽

F. Valcamonico ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Elderly Patients ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Safety Data ◽

Efficacy And Safety ◽

Expanded Access ◽

Expanded Access Program ◽

Download Full-text